BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2132 related articles for article (PubMed ID: 18538731)

  • 1. Tumor cell metabolism: cancer's Achilles' heel.
    Kroemer G; Pouyssegur J
    Cancer Cell; 2008 Jun; 13(6):472-82. PubMed ID: 18538731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism.
    Pathania D; Millard M; Neamati N
    Adv Drug Deliv Rev; 2009 Nov; 61(14):1250-75. PubMed ID: 19716393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mitochondrial permeability in cancer drug development.
    Berridge MV; Herst PM; Lawen A
    Mol Nutr Food Res; 2009 Jan; 53(1):76-86. PubMed ID: 19035550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.
    Winquist RJ; Boucher DM; Wood M; Furey BF
    Biochem Pharmacol; 2009 Aug; 78(4):326-34. PubMed ID: 19539800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New targets for cancer chemotherapy.
    Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA
    Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208
    [No Abstract]   [Full Text] [Related]  

  • 6. Mitochondria as therapeutic targets for cancer chemotherapy.
    Galluzzi L; Larochette N; Zamzami N; Kroemer G
    Oncogene; 2006 Aug; 25(34):4812-30. PubMed ID: 16892093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.
    Pennington JD; Wang TJ; Nguyen P; Sun L; Bisht K; Smart D; Gius D
    Drug Resist Updat; 2005 Oct; 8(5):322-30. PubMed ID: 16230045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Systemic and cellular pathways of anti-tumor action of plant adaptogenes].
    Arushanian EB
    Vopr Onkol; 2009; 55(1):15-23. PubMed ID: 19435193
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug resistance mediated by survival- and growth-promoting signaling pathways].
    Fujita N
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):567-71. PubMed ID: 19381028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoxygenase metabolism: roles in tumor progression and survival.
    Pidgeon GP; Lysaght J; Krishnamoorthy S; Reynolds JV; O'Byrne K; Nie D; Honn KV
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):503-24. PubMed ID: 17943411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPARC in cancer biology: its role in cancer progression and potential for therapy.
    Tai IT; Tang MJ
    Drug Resist Updat; 2008 Dec; 11(6):231-46. PubMed ID: 18849185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting TGFbeta-mediated processes in cancer.
    Romano MF
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):253-63. PubMed ID: 19333871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondria and cancer chemoresistance.
    Guerra F; Arbini AA; Moro L
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):686-699. PubMed ID: 28161329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondriotoxic compounds for cancer therapy.
    Fantin VR; Leder P
    Oncogene; 2006 Aug; 25(34):4787-97. PubMed ID: 16892091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular signal transduction pathway proteins as targets for cancer therapy.
    Adjei AA; Hidalgo M
    J Clin Oncol; 2005 Aug; 23(23):5386-403. PubMed ID: 15983388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of novel anticancer drug targets.
    Buolamwini JK; Assefa H
    Methods Mol Med; 2003; 85():3-28. PubMed ID: 12710193
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular biology. Cancer's perpetual source?
    Marx J
    Science; 2007 Aug; 317(5841):1029-31. PubMed ID: 17717165
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.
    Mousa SA; Petersen LJ
    Thromb Haemost; 2009 Aug; 102(2):258-67. PubMed ID: 19652876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer destruction in vivo through disrupted energy metabolism. Part III. Spontaneous drug resistance, selectivity of antineoplastic action, and strategies for intensifying tumor injury.
    Jones GR
    Physiol Chem Phys Med NMR; 1992; 24(3):195-212. PubMed ID: 1461933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of phosphatidylinositol 3-kinase signaling pathways in pancreatic cancer.
    Sun C; Rosendahl AH; Andersson R; Wu D; Wang X
    Pancreatology; 2011; 11(2):252-60. PubMed ID: 21625196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 107.